"Chief Executive Leonard Schleifer said in the release that the second quarter showcased "record net product sales of EYLEA, Dupixent, and Libtayo, as well as multiple regulatory achievements for Dupixent." Regeneron shares have lost 13% over the past three months as the S&P 500 has fallen about 2%."
Read More
"If omicron starts to surge, we need antibodies that will work," Chief Executive Officer Leonard Schleifer said in an interview on CNBC. "
Read More
"Along with increased patient use, Chief Executive Officer Leonard Schleifer said national trends in Covid infections in the coming weeks will be the most important variable for predicting third-quarter demand for the therapy."
Read More
"That was the message from Regeneron's Chief Executive Officer Leonard Schleifer during a conference call Thursday. "
Read More
""We believe our data will have positive implications for the likelihood of success of vaccines that target the same spike protein that REGN-COV2 targets," Regeneron CEO Leonard Schleifer told investors on Tuesday, according to a FactSet transcript of the call."
Read More
""We believe our data will have positive implications for the likelihood of success of vaccines that target the same spike protein that REGN-COV2 targets," Regeneron CEO Leonard Schleifer told investors on Tuesday, according to a FactSet transcript of the call."
Read More